Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer.

被引：2
|
作者：
Gajria, D. [1 ]
King, T. A. [1 ]
Pannu, H. [1 ]
Sakr, R. [1 ]
Seidman, A. D. [1 ]
Syldor, A. [1 ]
Patil, S. [1 ]
Maybody, M. [1 ]
Norton, L. [1 ]
Rosen, N. [1 ]
Hudis, C. [1 ]
Chandarlapaty, S. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.574
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
574
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Dual HER2 inhibition and paclitaxel in metastatic breast cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2015, 16 (02): : E57 - E57
  • [32] Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.
    Olson, E. M.
    Flores, L. M.
    Najita, J. S.
    Curley, C.
    Jeong, J.
    Murray, K.
    Savoie, J. J.
    Winer, E. P.
    Krop, I. E.
    CANCER RESEARCH, 2011, 71
  • [33] Genetic testing in a cohort of young patients with HER2-amplified breast cancer
    Eccles, D. M.
    Li, N.
    Handwerker, R.
    Maishman, T.
    Copson, E. R.
    Durcan, L. T.
    Gerty, S. M.
    Jones, L.
    Evans, D. G.
    Haywood, L.
    Campbell, I.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 467 - 473
  • [34] Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin
    Marcia R. Campbell
    Hui Zhang
    Shabnam Ziaee
    Ana Ruiz-Saenz
    Nathaniel Gulizia
    Julie Oeffinger
    Dhara N. Amin
    Deepika Ahuja
    Mark M. Moasser
    Catherine C. Park
    Breast Cancer Research and Treatment, 2016, 155 : 431 - 440
  • [35] Survival outcome in HER2-amplified metastatic colorectal cancer (mCRC).
    Sawada, Kentaro
    Okamoto, Wataru
    Nakamura, Yoshiaki
    Yamanaka, Takeharu
    Yuki, Satoshi
    Yoshino, Takayuki
    Komatsu, Yoshito
    Sakamoto, Naoya
    Fujii, Satoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [36] Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin
    Campbell, Marcia R.
    Zhang, Hui
    Ziaee, Shabnam
    Ruiz-Saenz, Ana
    Gulizia, Nathaniel
    Oeffinger, Julie
    Amin, Dhara N.
    Ahuja, Deepika
    Moasser, Mark M.
    Park, Catherine C.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 431 - 440
  • [37] Phase I study of dasatinib in combination with trastuzumab and paclitaxel in patients with HER2 positive metastatic breast cancer
    Gil, M.
    Martin, M.
    Antolin, S.
    Trigo, J. M.
    Guerrero, A.
    Vidal, L.
    Urruticoechea, A.
    Pandiella, A.
    Hernando, A.
    Ocana, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S180 - S180
  • [38] The activation of YES1 leads to the acquired resistance to neratinib in HER2-amplified breast and lung cancers
    Yamamoto, Hiromasa
    Takeda, Tatsuaki
    Suzawa, Ken
    Tomida, Shuta
    Miyauchi, Shunsaku
    Araki, Kota
    Nakata, Kentaro
    Miura, Akihiro
    Shien, Tadahiko
    Kitamura, Yoshihisa
    Sendo, Toshiaki
    Toyooka, Shinichi
    CANCER RESEARCH, 2020, 80 (16)
  • [39] YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers
    Takeda, Tatsuaki
    Yamamoto, Hiromasa
    Suzawa, Ken
    Tomida, Shuta
    Miyauchi, Shunsaku
    Araki, Kota
    Nakata, Kentaro
    Miura, Akihiro
    Namba, Kei
    Shien, Kazuhiko
    Soh, Junichi
    Shien, Tadahiko
    Kitamura, Yoshihisa
    Sendo, Toshiaki
    Toyooka, Shinichi
    CANCER SCIENCE, 2020, 111 (03) : 849 - 856
  • [40] A PHASE 2 STUDY OF TRASTUZUMAB EMTANSINE IN JAPANESE PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER
    Takahashi, S.
    Kashiwaba, M.
    Takao, S.
    Ito, Y.
    Doihara, H.
    Rai, Y.
    Matsubara, M.
    Kanatani, K.
    Masuda, N.
    ANNALS OF ONCOLOGY, 2013, 24 : 20 - 20
12345